Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
NCT07284043Phase 1Completed
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT1013 in secondary hyperparathyroidism (SHPT), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoints: Cumulative excretion of radioactivity at 91 days and Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure at 91 days. Started Nov 2025; status: completed.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT07284043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284043.